Table 1 Distribution of clinical and pathological factors in unicentric and multifocal/multicentric breast cancers

Age

≤40

14 (28.6)

35 (71.4)

p = 0.002

41-50

45 (24.7)

137 (75.3)

51-60

33 (13.1)

218 (86.9)

61-70

43 (13.4)

279 (86.6)

71-80

43 (16.1)

224 (83.9)

>80

13 (14.9)

74 (85.1)

Menopausal status

Premenopausal

58 (23.4)

190 (76.6)

p < 0.001

Postmenopausal

133 (14.6)

777 (85.4)

Histotype

Ductal infiltrating

123 (14)

755 (86)

p < 0.001

Lobular infiltrating

44 (30.8)

99 (69.2)

Mucinous

9 (16.4)

46 (83.6)

Apocrine

5 (21.7)

18 (78.3)

Papillary

4 (19)

17 (81)

Tubular

3 (15.8)

16 (84.2)

Other

3 (15.8)

16 (84.2)

Tumor size

1a (0.1 – 0.5 cm)

5 (9.4)

48 (90.6)

p < 0.001

1b (0.6 – 1 cm)

18 (9)

182 (91)

1c (1.1 – 2 cm)

74 (15.3)

410 (84.7)

2 (2.1 – 5 cm)

56 (17.2)

269 (82.8)

3 (>5 cm)

38 (39.6)

58 (60.4)

Nodal status

0

71 (10.2)

628 (89.8)

p < 0.001

1a

49 (20.4)

191 (79.6)

2a

28 (21.2)

104 (78.8)

3a

44 (50.6)

43 (49.4)

Tumor grade

1

40 (18.6)

175 (81.4)

p = 0.45

2

100 (15.3)

553 (84.7)

3

51 (17.6)

239 (82.4)

Lymphovascular invasion*

Absent

92 (12.3)

654 (87.7)

p < 0.001

Present

88 (24.6)

269 (75.4)

Estrogen receptors*

negative

76 (21.3)

280 (78.7)

p = 0.006

positive.

105 (14.7)

611 (85.3)

Progesteron receptors*

negative

63 (20)

252 (80)

p = 0.08

positive

118 (15.6)

636 (84.4)

Mib-1

≤15%

74 (14.6)

432 (85.4)

p = 0.4

>15%

98 (17.5)

461 (82.5)

Her-2/neu*

not overexpressed

99 (13.7)

625 (86.3)

p = 0.019

overexpressed

46 (21.2)

171 (78.8)